Edition:
United Kingdom

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

20.54USD
14 Dec 2017
Change (% chg)

$-0.26 (-1.25%)
Prev Close
$20.80
Open
$20.85
Day's High
$21.08
Day's Low
$20.08
Volume
359,587
Avg. Vol
378,041
52-wk High
$21.08
52-wk Low
$9.69

Latest Key Developments (Source: Significant Developments)

Halozyme reports Q3 EPS of $0.02
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Halozyme Therapeutics Inc :Halozyme reports third quarter 2017 results.Q3 earnings per share $0.02.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Q3 revenue $63.7 million versus i/b/e/s view $59 million.Sees FY 2017 ‍net revenue of $265 million to $280 million​.Qtrly ‍ cash, cash equivalents & marketable securities were $316.9 million at Sept. 30, 2017, versus $297.5 million at June 30, 2017​.  Full Article

Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Halozyme Therapeutics Inc :Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​.Halozyme Therapeutics Inc - will receive a $15 million milestone payment from Janssen following dosing of third patient in a phase 3 trial​.  Full Article

Halozyme reports second quarter 2016 financial results
Tuesday, 9 Aug 2016 

Halozyme Therapeutics Inc : Halozyme reports second quarter 2016 financial results . Q2 revenue $33.3 million versus I/B/E/S view $29.9 million . Sees FY 2016 revenue $140 million to $150 million . Q2 loss per share $0.21 . Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Sees 2016 operating expenses to continue to be in range of $245 million to $260 million .FY2016 revenue view $138.7 million -- Thomson Reuters I/B/E/S.  Full Article

Halozyme to resume enrollment in Phase 1B trial evaluating PEGPH20
Monday, 25 Jul 2016 

Halozyme Therapeutics Inc : Resumed enrollment, dosing patients in phase 1B trial evaluating investigational new drug, PEGPH20, in combination with KEYTRUDA . Revised protocol has been submitted to all institutional review boards (IRB) and is pending feedback from FDA .Majority of institutional review boards have completed their review and approved revised protocol allowing study to resume.  Full Article

Halozyme announces agreement to refinance debt
Wednesday, 8 Jun 2016 

Halozyme Therapeutics Inc : Entered into agreement with Oxford Finance Llc and Silicon Valley Bank to refinance its existing senior secured loan facility . Under new financing agreement, Halozyme borrowed $55 million at a fixed rate of 8.25% . New debt facility provides option to borrow additional $15 million in 2017 . Interest-Only repayment provision results in $44 million increase to expected cash balance through 2017 . Under new financing agreement, Halozyme used proceeds to refinance its existing long-term debt . Agreement will result in a $22 million per-year increase to company's expected cash balance at end of 2016 and 2017 . Expecting a year-end cash balance of $170 million to $190 million .Announces agreement to refinance debt, increases 2016 guidance for year-end cash balance.  Full Article

Halozyme Q1 loss per share $0.16
Monday, 9 May 2016 

Halozyme Therapeutics Inc : Halozyme therapeutics inc sees 2016 net revenues to be in range of $130 million to $145 million . Halozyme therapeutics inc sees 2016 cash flow to be in range of $45 million to $65 million . Fy2016 earnings per share view $-0.98, revenue view $127.9 million -- Thomson Reuters I/B/E/S . Halozyme reports first quarter 2016 financial results . Q1 loss per share $0.16 . Q1 revenue $42.5 million versus $18.7 million . Q1 revenue view $29.7 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Inc maintains FY 2016 net revenues guidance
Monday, 29 Feb 2016 

Halozyme Therapeutics Inc:For Fy 2016, the company maintains its previously announced guidance of Net revenues to be in the range of $110 million to $125 million.  Full Article

Halozyme says closing Of $150 Million Royalty-Backed Debt Financing
Tuesday, 26 Jan 2016 

Halozyme Therapeutics Inc:Closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management.Debt is secured by future royalties of ENHANZE(tm) products, received only from Halozyme's collaborations with Roche and Baxalta.  Full Article

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage: